Katy, I believe Ferghana would shortlist respiratory pharma company's based on knowledge of drug pipelines, balance sheet and possibly personnel. They would then explain commercial opportunities to relevant pharma decision makers. If their is genuine interest, then potential partners would require more detailed data to undertake due diligence.
To access this data, they would sign NDA's... which they have. From there, exhaustive due diligence.
Ferghana have exclusive rights to negotiate any possible transactions, so you can discard Evaluate ( incidentally, invion 103 partnering opportunity was last updated by them in 2014). Hang in there.
Ferghana Partners, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(20.0%) |
Mkt cap ! $25.69M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $5.78K | 1.445M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 12797949 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7472779 | 27 |
View Market Depth
| Last trade - 14.20pm 28/06/2024 (20 minute delay) ? |
| IVX (ASX) Chart |